Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Conditions:   Relapsed/Refractory Chronic Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Leukemia Interventions:   Drug: Ibrutinib;   Drug: Venetoclax Sponsor:   Swiss Group for Clinical Cancer Research Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials